Cellzome adopts Proteome Sciences TMT isobaric mass tag technology into its chemical proteomics platforms

21st April 2008

Proteome Sciences plc, has entered into a supply agreement with Cellzome AG of Heidelberg, Germany for its proprietary tandem mass tag technology (TMT®). Cellzome will use TMTsixplex in its proprietary chemical proteomics platform for the analysis of protein-drug and protein-protein interactions.

Cellzome has been using isobaric mass tags in its chemical proteomics platform for several years and was an early beta test site for TMTsixplex. Following a thorough evaluation of TMT, Cellzome is now integrating TMTsixplex as an isobaric mass tagging technology for its own research.

Marcus Bantscheff, Director Analytical Sciences at Cellzome said:

"We have found the TMTsixplex a useful tool for our quantitative proteomics studies. With this isobaric mass tagging technology we can now do six point measurements in a single mass spectrometric experiment. This is particularly useful when using our proprietary KinobeadsTM technology where we can quantitatively measure the extent that compounds or drugs interact with kinases within cells and tissues."

Christopher Pearce, Chief Executive of Proteome Sciences commented:

“This endorsement by Cellzome, one of the global leaders in the field demonstrates the utility and strong commercial value of our proprietary Tandem Mass Tag® technology and the strength of our underlying patent portfolio. With TMTsixplex we offer a patented technology that creates fast, flexible and cost-efficient proteomic workflows. Cellzome has clearly recognised the improvements in speed and reproducibility of programmes by adopting TMTsixplex into its chemical proteomics platforms and we are delighted to be providing them and their customers with an enhanced product. This moves Tandem Mass Tags into new high value applications in drug discovery/development and that is highly complementary to the earlier applications in biomarker discovery, validation and assay development.”